Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Sarnath Singh"'
Autor:
Kaci Kopec, Tara Jarboe, Michael Guo, Nicole R. DeSouza, Sarnath Singh, Augustine Moscatello, Humayun K. Islam, Jan Geliebter, Raj K. Tiwari
Publikováno v:
Cancer Research. 83:3915-3915
Papillary thyroid cancer (PTC) is a well-differentiated and highly treatable cancer with a 5-year survival rate of almost 99%. In contrast, anaplastic thyroid cancer (ATC) lacks differentiation and loses its thyroid-like functions, including lack of
Autor:
Raj K. Tiwari, Marc Zemel, Dionysios Liveris, Sarnath Singh, Jan Geliebter, Gary Friedman, Jeffry M. Bulson, Sin Park, Irina L. Derkatch
Publikováno v:
Mycoses
Background Onychomycosis affects almost 6% of the world population. Topical azoles and systemic antifungal agents are of low efficacy and can have undesirable side effects. An effective, non-invasive therapy for onychomycosis is an unmet clinical nee
Autor:
Tara Jarboe, Kaci Kopec, Nicole R. DeSouza, Sarnath Singh, Augustine Moscatello, Jan Geliebter, Xiu-Min Li, Raj K. Tiwari
Publikováno v:
Cancer Research. 82:243-243
Only 2% of thyroid cancer (TC) cases are anaplastic thyroid cancer (ATC), but this rare, undifferentiated cancer with a highly inflamed tumor microenvironment (TME) presents universally as stage IV with a 5-year survival rate of 3%. Due to its loss o
Autor:
Kaci Kopec, Tara Jarboe, Mordechai Sternman, Nicole R. DeSouza, Sarnath Singh, Augustine Moscatello, Jan Geliebter, Raj K. Tiwari, Xiu-Min Li
Publikováno v:
Cancer Research. 82:1410-1410
Anaplastic thyroid cancer (ATC) is an undifferentiated thyroid cancer. A hallmark of ATC is increased inflammatory cytokine expression and inflammatory cell infiltration in the tumor microenvironment that is responsible for its aggressive nature. In
Autor:
Nicole DeSouza, Michelle Carnazza, Danielle Quaranto, Tara Jarboe, Kaci Kopec, Sarnath Singh, Augustine Moscatello, Jan Geliebter, Raj K. Tiwari
Publikováno v:
Cancer Research. 82:67-67
Anaplastic Thyroid Cancer (ATC) is one of the most aggressive forms of thyroid cancer, with only a 4% survival rate with metastatic disease. Further, ATC is highly refractory and resistant to traditional therapeutics, resulting in poor patient outcom
Autor:
Raj K. Tiwari, Augustine Moscatello, Nicole DeSouza, Sarnath Singh, Xiu-Min Li, Tara Jarboe, Jan Geliebter
Publikováno v:
Cancer Research. 81:317-317
Anaplastic thyroid cancer's (ATC) undifferentiated, inflammatory nature makes it one of the most aggressive cancers, with a five-year survival rate of only 4% when metastatic. ATC is a rare cancer that is refractory to conventional therapeutic modali
Autor:
Marc K. Wallack, Robert Bednarczyk, Raj K. Tiwari, Rachana Maniyar, Neha Y. Tuli, Debabrata Banerjee, Marc Wallack Wallack, Sarnath Singh, Jan Geliebter, Ghada Ben Rahoma, Abraham Mittelma
Publikováno v:
International Journal of Translational Science. 2016:33-60
Autor:
Sanjukta Chakraborty, Rachana R. Maniyar, Sina Dadafarin, Ghada Ben Rahoma, Sarnath Singh, Augustine Moscatello, Jan Geliebter, Raj K. Tiwari
Publikováno v:
Cancer Research. 79:3237-3237
Anaplastic thyroid cancer(ATC) is a rare but extremely aggressive form of endocrine malignancy that accounts for only 1-2% of total thyroid cancer cases but responsible for 20-30% of annual mortality from thyroid cancer in the USA. Genetic lesion lan
Autor:
Ghada Ben Rahoma, Rachana Maniyar, Sanjukta Chakraborty, Sarnath Singh, Anitha Srinivasan, Abraham Mittelman, Jan Geliebter, Raj K. Tiwari
Publikováno v:
Cancer Research. 79:3562-3562
Despite the exciting progresses in the treatment of breast cancer, the effectiveness of the current therapeutic modalities is still restricted by drug toxicity, resistance, and lack of predictive and prognostic biomarkers. Breast cancer continues to
Autor:
Raj K. Tiwari, Mingzhuo Cou, Xiu-Min Li, Ghada Ben Rahoma, Changda Liu, Rachana Maniyar, Fei Mo, Michelle Carnazza, Sanjukta Chakraborty, Sarnath Singh, Tara Jarboe, Martin J. Walsh
Publikováno v:
Cancer Research. 79:1855-1855
Breast cancer is the most common cancer among women worldwide, contributing to 25.4% of newly diagnosed cancer cases in 2018. Triple negative breast cancer (TNBC) accounts for 10-20% of the breast cancer cases and represents an unmet clinical need be